Veracyte director sells 10,000 shares under plan

VERACYTE, INC. director Robert S. Epstein reported an open-market sale of 10,000 shares of common stock on May 20, 2026 at a weighted average price of $44.01 per share, with individual sale prices ranging from $44.00 to $44.10.

Rhea-AI Filing Summary

VERACYTE, INC. director Robert S. Epstein reported an open-market sale of 10,000 shares of common stock on May 20, 2026 at a weighted average price of $44.01 per share, with individual sale prices ranging from $44.00 to $44.10.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following these sales, Epstein directly owns 52,446 shares of Veracyte common stock.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider EPSTEIN ROBERT S

Role Director

Sold 10,000 shs ($440K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$44.0129	$440K

Holdings After Transaction: Common Stock — 52,446 shares (Direct)

Footnotes (2)

1. F1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2025.
2. F2. Represents weighted average sales price. Sale prices for the transactions range from $44.00 to $44.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $44.0129 per share Post-transaction holdings: 52,446 shares +1 more

4 metrics

Shares sold 10,000 shares Open-market sale of Veracyte common stock on May 20, 2026

Weighted average sale price $44.0129 per share Reported for the May 20, 2026 open-market sale

Post-transaction holdings 52,446 shares Shares of Veracyte common stock owned directly after the sale

Sale price range $44.00–$44.10 per share Range of individual sale prices noted in footnote

Key Terms

Rule 10b5-1 plan, weighted average sales price, open-market sale, Form 4

4 terms

Rule 10b5-1 plan regulatory

"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sales price financial

"Represents weighted average sales price. Sale prices for the transactions range from $44.00 to $44.10."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Veracyte (VCYT) director Robert S. Epstein report?

Robert S. Epstein reported selling 10,000 shares of Veracyte common stock. The sale occurred in the open market on May 20, 2026 under a pre-arranged Rule 10b5-1 trading plan he adopted on December 5, 2025.

At what prices did Robert S. Epstein sell Veracyte (VCYT) shares?

Epstein’s Veracyte share sales had a weighted average price of $44.01 per share. The individual sale prices ranged from $44.00 to $44.10, according to the Form 4 footnote describing the detailed transaction pricing information.

How many Veracyte (VCYT) shares does Robert S. Epstein own after this sale?

After selling 10,000 shares, Epstein directly holds 52,446 Veracyte common shares. This post-transaction ownership figure comes from the Form 4, which reports the number of shares beneficially owned following the disclosed open-market sale.

Was Robert S. Epstein’s Veracyte (VCYT) stock sale made under a Rule 10b5-1 plan?

Yes, the Form 4 states the transactions were made under a Rule 10b5-1 plan. This trading plan was adopted by Epstein on December 5, 2025, indicating the sales were pre-arranged rather than newly decided at the time of execution.

What type of transaction code was used in Robert S. Epstein’s Veracyte (VCYT) Form 4?

The Form 4 lists the transaction code “S,” indicating an open-market or private sale of common stock. The filing further clarifies the action as an open-market sale, consistent with the reported share price range and trading details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EPSTEIN ROBERT S

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		S(1)		10,000	D	$44.0129(2)	52,446	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $44.00 to $44.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)